Post-earnings recap
Reported
Tue, Feb 24, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Exelixis is still in a development phase, with a loss per share slightly better than expected. However, the lack of revenue figures and guidance may have contributed to the stock's decline of 2.18% following the announcement. Investors will likely be looking for more concrete updates in future quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | +3.23% |
| Revenue | N/A | N/A | N/A |
Overall, management remains focused on advancing their pipeline. They acknowledged the challenges ahead but expressed confidence in their strategy.
Management highlighted ongoing development efforts and future potential.
They emphasized the importance of upcoming clinical trial results.